This company has been marked as potentially delisted and may not be actively trading. Gemphire Therapeutics (GEMP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock GEMP vs. NNVC, HILS, TAOX, IBIO, GRAY, OBSV, AEON, MTNB, AEZS, and NRBOShould you be buying Gemphire Therapeutics stock or one of its competitors? The main competitors of Gemphire Therapeutics include NanoViricides (NNVC), Hillstream BioPharma (HILS), Synaptogenix (TAOX), iBio (IBIO), Graybug Vision (GRAY), ObsEva (OBSV), AEON Biopharma (AEON), Matinas Biopharma (MTNB), Aeterna Zentaris (AEZS), and NeuroBo Pharmaceuticals (NRBO). Gemphire Therapeutics vs. Its Competitors NanoViricides Hillstream BioPharma Synaptogenix iBio Graybug Vision ObsEva AEON Biopharma Matinas Biopharma Aeterna Zentaris NeuroBo Pharmaceuticals NanoViricides (NYSE:NNVC) and Gemphire Therapeutics (NASDAQ:GEMP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends. Do insiders & institutionals have more ownership in NNVC or GEMP? 10.3% of NanoViricides shares are owned by institutional investors. Comparatively, 17.5% of Gemphire Therapeutics shares are owned by institutional investors. 4.6% of NanoViricides shares are owned by insiders. Comparatively, 22.7% of Gemphire Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer NNVC or GEMP? In the previous week, NanoViricides had 1 more articles in the media than Gemphire Therapeutics. MarketBeat recorded 1 mentions for NanoViricides and 0 mentions for Gemphire Therapeutics. NanoViricides' average media sentiment score of 0.50 beat Gemphire Therapeutics' score of 0.00 indicating that NanoViricides is being referred to more favorably in the media. Company Overall Sentiment NanoViricides Positive Gemphire Therapeutics Neutral Which has more risk and volatility, NNVC or GEMP? NanoViricides has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Gemphire Therapeutics has a beta of 2.82, indicating that its stock price is 182% more volatile than the S&P 500. Is NNVC or GEMP more profitable? NanoViricides' return on equity of -87.90% beat Gemphire Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NanoViricidesN/A -87.90% -78.69% Gemphire Therapeutics N/A -419.70%-173.05% Which has higher valuation and earnings, NNVC or GEMP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNanoViricidesN/AN/A-$8.29M-$0.70-2.06Gemphire TherapeuticsN/AN/A-$23.64MN/AN/A SummaryNanoViricides beats Gemphire Therapeutics on 5 of the 8 factors compared between the two stocks. Get Gemphire Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GEMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GEMP vs. The Competition Export to ExcelMetricGemphire TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.67M$837.08M$5.83B$9.78BDividend YieldN/A4.84%4.40%4.05%P/E RatioN/A1.1831.3026.05Price / SalesN/A152.89455.25117.77Price / CashN/A19.5638.0259.36Price / Book1.206.649.536.60Net Income-$23.64M-$4.94M$3.26B$265.65M Gemphire Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GEMPGemphire TherapeuticsN/A$0.65+1.7%N/A-82.5%$9.67MN/A0.009NNVCNanoViricides0.7239 of 5 stars$1.54flatN/A-21.7%$24.75MN/A-2.1420HILSHillstream BioPharmaN/A$1.20-2.8%N/AN/A$21.12MN/A-1.671Gap UpTAOXSynaptogenixN/A$8.34+12.9%N/AN/A$10.27MN/A-0.834Earnings ReportGap UpIBIOiBio1.8709 of 5 stars$0.57-2.3%$5.00+772.4%-60.3%$9.47M$375K0.00100News CoverageGap DownGRAYGraybug VisionN/A$2.76+0.7%N/A-33.3%$8.64MN/A-1.6027Gap UpHigh Trading VolumeOBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050AEONAEON Biopharma2.8993 of 5 stars$0.69+5.0%$360.00+52,134.5%-98.9%$7.79MN/A3.835Gap DownMTNBMatinas Biopharma0.6973 of 5 stars$1.48-7.5%N/AN/A$7.53MN/A-0.3130AEZSAeterna ZentarisN/A$3.58-0.4%N/A-55.3%$6.42M$2.37M-0.2420NRBONeuroBo PharmaceuticalsN/A$0.64+1.3%N/A-82.5%$5.50MN/A0.0010Gap Up Related Companies and Tools Related Companies NanoViricides Competitors Hillstream BioPharma Competitors Synaptogenix Competitors iBio Competitors Graybug Vision Competitors ObsEva Competitors AEON Biopharma Competitors Matinas Biopharma Competitors Aeterna Zentaris Competitors NeuroBo Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GEMP) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemphire Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemphire Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access